InvestorsHub Logo
Followers 47
Posts 5233
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Tuesday, 06/27/2017 12:15:12 AM

Tuesday, June 27, 2017 12:15:12 AM

Post# of 34576

Glynn Wilson, Chairman and CEO of TapImmune, stated: "We are pleased with the continued interest and support for TapImmune. This investment will fund us through several significant clinical milestones in the advancement of our novel T-cell vaccines for breast and ovarian cancer. In addition, we believe that the warrant exercise illustrates the support our current investors have for our continued progress and successful clinical execution. We believe that these events can provide a catalyst for our future growth in one of the most rapidly growing sectors of the oncology market."


Given the number of raises done here, they must have this verbiage ready to go to press at push of a button lmfao.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News